Emulate Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023

Boston, MA – March 2, 2023 – Emulate, Inc., a leading provider of next-generation in vitro models, today announced that it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.  

This year’s list highlights the businesses who are setting the standard in their respective industries. In addition to the World’s 50 Most Innovative Companies, 540 organizations are recognized across 54 sectors and regions.  

“To once again be among this distinguished group of innovators, especially those reshaping the biotech industry, is truly an honor,” said Emulate CEO Jim Corbett. “Our team works relentlessly to break new scientific ground by creating preclinical models that combine human biology with microphysiological systems (MPS), better known as Organ-Chips. By embracing these human-centric technologies, we can more accurately predict a drug’s effects, allowing us to improve patient safety and bring new therapies to those who need them most—something we have demonstrated consistently over the last year.” 

2022 was a year of unprecedented achievement for the company. After completing the single largest Organ-Chip study to date, Emulate researchers published “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Communications Medicine, part of Nature Portfolio. Their findings demonstrated that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%. An economic evaluation from this first-of-its-kind study also indicated that routine use of the Emulate human Liver-Chip could generate $3 billion per year for small molecule drug development by driving an increase in research and development productivity. 

Emulate continued to push Organ-Chips into new areas of study by releasing several new applications this year. Their adeno-associated virus (AAV) transduction application for the Emulate human Liver-Chip enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors in a validated, human-relevant liver model and get results in weeks, not months as with animal models. Their colon immune cell recruitment application enables the most human-relevant preclinical assessment of drug candidates for inflammatory bowel disease (IBD). 

“In December 2022, we celebrated the signing of the FDA Modernization Act 2.0 into law as well as the establishment of an EU-wide action plan from the European Parliament to phase out animal models from research and testing,” said Mr. Corbett. “Companies can now use alternatives, such as MPS and Organ-Chips, in their novel Investigational New Drug (IND) submissions. At our upcoming inaugural Global MPS Day, we will bring together key opinion leaders to discuss the latest advancements in this technology and its potential impact on uncovering new therapies for the thousands of diseases without cures.” 

Fast Company’s editors and writers sought out the companies making the biggest strides around the globe. They also judged nominations received through their application process. 

The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year. It provides a firsthand look at the inspiring and innovative efforts of companies across all sectors of the economy. 

“What a strange and thrilling year it has been to honor this year’s Most Innovative Companies. This year’s list compiles some of the most cutting-edge ground-breakers who are changing our world every single day, from legacy organizations like McDonald’s to upstarts like MrBeast and institutions such as NASA. Everyone on this list does something completely, uniquely different, yet they all have one thing in common: innovation,” said Fast Company editor-in-chief Brendan Vaughan.

About Emulate, Inc.    

Emulate is igniting a new era in human health with industry-leading Organ-on-a-Chip technology. The Human Emulation System provides a window into the inner workings of human biology and disease, offering researchers an innovative technology designed to predict human response with greater precision and detail than conventional cell culture or animal-based experimental testing. Pioneered at the Wyss Institute for Biologically Inspired Engineering at Harvard University and backed by Northpond Ventures, Founders Fund, and Perceptive Advisors, Organ-on-a-Chip technology assists researchers across academia, pharma, and government industries through its predictive power and ability to recreate true-to-life human biology. To learn more, visit emulatebio.com or follow us on LinkedIn and Twitter.    

About Fast Company 

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at fastcompany.com

Media Contact:   

Emulate, Inc.  

Michael Sullivan  


+1 503-799-7520